Targeting central nervous system pathologies with nanomedicines.

Area of Science:

• Neuroscience
• Nanotechnology
• Pharmacology

Background:

• Delivering therapeutics to the central nervous system (CNS) is a major challenge in drug development.
• The blood-brain barrier (BBB) significantly restricts the passage of therapeutic agents into the brain, hindering treatment for neurological diseases.

Purpose of the Study:

• To explore strategies for utilizing targeted nanocarriers to overcome the BBB for enhanced CNS drug delivery.
• To discuss the benefits of receptor-mediated transport for brain therapeutics.

Main Methods:

• Review of current literature on nanocarrier design and targeting strategies for CNS delivery.
• Analysis of receptor-mediated transport mechanisms across the BBB endothelium.
• Discussion of challenges and recent advancements in the field.

Main Results:

• Targeted nanocarriers can leverage endogenous receptors to facilitate transport across the BBB.
• Receptor-mediated transport offers advantages over conventional methods like BBB permeabilization or intracranial depots.
• Various strategies for nanocarrier targeting to the CNS are being developed.

Conclusions:

• Targeted nanocarriers represent a significant advancement in overcoming BBB limitations for CNS drug delivery.
• Further research into nanocarrier strategies is crucial for treating neurological pathologies effectively.